anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression is a serious medical illness that can recur more than once in a person's lifetime. Effective treatment methods are needed to maintain a state of remission in people who have had prior episodes of depression. IPT is a brief and highly structured type of psychotherapy that addresses interpersonal issues associated with depression. Previous studies have shown that it is an effective method for treating depression. This study will evaluate the effectiveness of maintenance ITP in preventing relapse of depression in women who have required combined psychotherapy and pharmacotherapy treatment to obtain remission of depressive symptoms.

Participants in this open label study will be recruited from a previous study, "Maintenance Psychotherapy in Recurrent Depression: Study I." In this study participants will initially receive weekly sessions of IPT as well as medication treatment with fluoxetine. Any participants who do not reach remission of depressive symptoms after 6 weeks will be given other standard treatments for depression. Once remission of depressive symptoms is reached, participants will continue receiving weekly IPT and fluoxetine treatment for 20 weeks. After 20 weeks, fluoxetine treatment will be discontinued, and all participants will receive IPT alone for 6 weeks before entering the maintenance phase of the study. Upon entrance into this phase, participants will be randomly assigned to receive IPT weekly, biweekly, or monthly for 18 months. Functioning and depressive symptoms will be assessed at Month 24.
PURPOSE: A cosmetic composition for skin whitening comprising the extract of Excoecaria bicolor and a production method of the Excoecaria bicolor extract are provided, which Excoecaria bicolor extract inhibits activity of tyrosinase participating in a skin darkening pathway, and inhibits melanine formation without skin stimulation. CONSTITUTION: The cosmetic composition for skin whitening comprises 0.001 to 10 wt.%, preferably 0.01 to 5 wt.% of the extract of Excoecaria bicolor, wherein the composition has a formulation selected from soft lotion, astringent lotion, nutritive lotion, eye cream, nutritive cream, massage cream, powder, essence, pack, ointment and spray. The method for producing the Excoecaria bicolor extract comprises the steps of: (a) adding one or more solvents selected from C1-4 anhydrous or hydrous lower alcohol, a mixture of water and alcohol, acetone and 1,3-butyleneglycol into the dried Excoecaria bicolor, and heating the mixture at 78 to 200 deg. C for 5 to 24 hours; (b) maturing the Excoecaria bicolor extract at 4 to 15 deg. C for 3 to 20 days; (c) concentrating the matured Excoecaria bicolor extract at 60 to 80 deg. C under reduced pressure, and extracting the concentrated Excoecaria bicolor extract with one or more solvents selected from ethylacetate, diethylether and methylenechloride one or more times; and (d) concentrating an organic layer of the Excoecaria bicolor extract under reduced pressure and drying the concentrated Excoecaria bicolor extract.
A method of inducing a generalized immune response, includes administering to a subject an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, thereby inducing a generalized immune response to infection by a pathogen in a subject. A prophylactic or therapeutic composition for inducing a generalized immune response, includes an immunologically effective amount of one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46. A method of distinguishing a subject infected with a pathogen from an uninfected subject, includes detecting an antibody in the subject that selectively binds one or more isolated immunogenic peptides comprising an amino acid sequence of SEQ. ID NOs: 1-46, wherein the presence of the antibody indicates that the subject is infected with the pathogen. A general method to discover broadly protective components for a vaccine is also disclosed.
Introduction: The American Thoracic Society recommends not walking with the patient or client during the Six Minute Walk Test (6MWT). However, this recommendation raises safety concerns for individuals at increased risk of falls. Given the recommendations and concerns, the effects of guarding during the 6MWT has not been investigated. Purpose: The purpose of this study was to determine if guarding during the 6MWT affected gait speed and distance walked. Methods: Participants were randomized into a 'guarded first' vs 'guarded second' condition. Data were analyzed using a one-sample t-test, Pearson Correlation Coefficients, Intraclass Correlation Coefficients (ICC), and Bland Altman plots to assess differences and relationships for gait speed and distance walked between the guarded and unguarded trials.
A system and method for tracking performance of a physical activity of a user on a field are provided. The system comprises a visual aid unit and a controller. The controller is configured to receive sensor data indicative of at least one of position and direction of movement of the user on the field. The sensor data is generated in relation to a first performance of the physical activity by the user. The controller analyzes the sensor data to generate visual indicators for the user. The controller controls the visual aid unit to project the generated visual indicators during a second performance of the physical activity by the user for reference of the user. The visual indicators are configured to aid in improving the performance of the user in relation to the physical activity.
Stroke is an enormous international public health concern, particularly in the developing world where there are limited resources available to provide for an aging population. One of the main contributors to stroke incidence is the highly prevalent Chagas disease, a parasitic infection affecting an estimated 18 million individuals and a major cause of heart failure in Latin America. Chagas disease conveys stroke risk through two established mechanisms: structural cardiac disease and chronic inflammation. Although inflammation is associated with an increased risk of ischemic stroke and poorer outcome, its role has been largely linked to atherogenesis. Chronic inflammation can result in endothelial dysfunction and stimulate the hemostatic system, increasing systemic fibrin production and platelet activation. Brain atrophy has also been associated with chronic inflammation. Adults, young and old, who develop a secondary cardiomyopathy from Chagas are therefore at higher risk of cardioembolism and neurodegeneration. Stroke patients usually survive, but can be left with significant disability affecting their health status, productivity, and quality of life. These factors impact caregivers as well. Thus, the social and economic consequences of stroke are vast. During our R21 planning grant period, we were able to establish a collaborative infrastructure between the research groups in Brazil and the United States and collect preliminary data. We found an association between Chagas disease and stroke that was independent of cardiomyopathy. Cognitive impairment and brain atrophy were also associated with Chagas disease independently of cardiomyopathy. Biomarkers orosomucoid, neprilysin, interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) were identified as diagnostic and therapeutic targets in Chagas disease. As part of this phase, we will address three specific aims: (1) to establish brain magnetic resonance imaging markers of stroke risk in patients with Chagasic congestive heart failure (CM); (2) to determine whether biomarkers can predict stroke risk in patients with Chagasic CM; and (3) to evaluate the efficacy of antiplatelet treatment in decreasing microembolization rate in patients with Chagasic CM. The long-term goal of this project is to establish non-invasive methods of stroke risk stratification and prediction of stroke outcome in patients with Chagas disease. This work will also facilitate the development of novel anti-trypanosomal, anti-inflammatory, and antithrombotic strategies for stroke prevention and management in Brazil.
NEW MATERIAL:A compound expressed by formula I {p is an integer 0-2; Y is H or group expressed by the formula OR [R is H, lower alkyl, lower alkoxycarbonyl, acyl or formula II (m is 1 or 2)] at the 5- or 8-position; n is an integer 1-3, except when p is 0 and Y is H] or a salt thereof. EXAMPLE:8-Hydroxy-2-nitratomethyl-7-nitro-1,4-benzodioxane. USE:A medicine, treating agent and preventing agent for ischemic cardiopathy and cardiac insufficiency, e.g. angina pectoris or cardiac infarction, etc., and a drug effective for blood pressure control in surgical operation, more powerful pharmacological action, e.g. arterial or venous vasodilator action, etc., and higher safety than the well-known nitro agents, e.g. nitroglycerol or isosorbide dinitrate, etc. PREPARATION:For example, a compound expressed by formula II is nitrated with a nitrating agent, e.g. acetic acid-fuming nitric acid, in or without a solvent, e.g. acetonitrile, at 0--40 deg.C to afford the aimed compound expressed by formula I.
Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
After successful extubation, patients will be transferred to PACU. Patients will receive a bolus dose of 5 mg nalbuphine then PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr with self-administration bolus of 0.5ml with 15 min lock-out time.
Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled "Study Drug". The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered.
This pilot study is being conducted to establish safety, however the study team will make multiple measures to measure for efficacy as well. The study team hypothesizes that human split-thickness skin grafts will safely respond similar to the porcine model when treated with the Fractional Carbon Dioxide (FxCO2) laser and have significantly less secondary contracture than control sites. The great majority of laser studies have addressed treatment of established scars. Ideally, treatment modalities could be moved into the acute period of injury, to shorten the recovery time of thermal burns by decreasing the time to maximum recovery, and mitigate scar formation. The current study will address the impact on treatment of skin graft applied in the treatment of acute burn wounds. Preliminary work completed by our team has confirmed that the red Duroc porcine model is a good model of hypertrophic scar formation in humans, and early use of the FxCO2 on split-thickness skin grafts decreased secondary contracture. Further, the study team has identified a period of 19 weeks between the time custom-made compression garments are ordered and actually applied with benefit to the patient. The study team has identified a "therapeutic donut hole" in which they have no efficacious alternative to offer until about 19 weeks. In these patients who had larger burn returning to the OR for additional procedures, the study team was able to offer FxCO2 treatment as a "salvage" therapy. With this, the study team has demonstrated safety for the skin graft and anecdotal efficacy. The study team proposes a pilot study to prospectively demonstrate safety in a controlled study and attempt to establish efficacy of early (post grafting day 7-10) FxCO2 laser treatment of split-thickness skin graft applied in the treatment of burn injuries.
A polymer comprises units of formulae (I) and (II): wherein B, s, m, n and A are as defined in the specification. There are also provided process for preparing them and their use in therapy, e.g. when A includes a therapeutic agent. The present invention provides an enhanced, generally water-soluble polymer comprising safe, low molecular weight components, which is also fully biodegradable down to these components. The drug entity may be added to one of the monomer components prior to polymerisation which conveys the added advantage that free drug cannot become trapped in the polymer matrix unless it is deliberately added during or after polymeirisation. The polymer system of this invention allows the addition of hydrophobic drugs with reduced risk of. the solubility problems seen with other polymer systems while still allowing high levels of drug loading. Thus, an additional feature of this invention is the inherent flexibility to design the polymer size and drug loading ratios for optimal solubility, for example, whilst being able to exploit useful characteristics; of larger polymer systems, such as tissue, organ or plasma retention, if desirable, without the inherent safety issues associated with toxic accumulation of a non-biodegradable system. The loading of drug is highly controllable at the polymerisation step and other components or drugs can additionally be added to the polymerisation step to become additionally incorporated into the polymer.
A server agent application receives a uniform resource locator (URL) from a client agent application, the URL including an identifier for a graphical resource. The server agent application determines, based upon the URL, that a third-party application is to provide the graphical resource. The server agent application causes an intermediate application to be launched. The intermediate application requests a webpage from the third-party application, the webpage including a security token for a user session between the client agent application and the third-party application. The intermediate application receives the webpage and constructs a modified URL based upon the URL and the security token included in the webpage. The intermediate application transmits the modified URL to the third-party application, wherein the third-party application causes the client agent application to receive the graphical resource based upon the modified URL.
Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
The relationships between the thyroid and the heart are close and complex. In rare cases, hyperthyroidism induced by Graves' disease can be complicated by an acute myocarditis, which may be life-threatening. We report the case of a 41-year-old woman with Graves' disease not controlled by antithyroid drugs, hospitalized for odynophagia, palpitations due to atrial fibrillation, diffuse ST elevation on ECG and an increase in cardiac troponin. Coronary angiography was normal, cardiac MRI confirmed acute myocarditis. The evolution was favorable after a phase marked by supraventricular and ventricular rhythm disorders. The diagnostic and therapeutic challenge of this association are discussed, with a review of the literature.
Lamotrigine, an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, its molecular formula is C9H7N5Cl2, and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pKa of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:

Lamotrigine orally disintegrating tablets are supplied for oral administration. The tablets contain 25 mg (white to off-white), 50 mg (white to off-white), 100 mg (white to off-white), or 200 mg (white to off-white) of lamotrigine and the following inactive ingredients: amino methacrylate copolymer, aspartame, black currant flavor, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, peppermint flavor, pregelatinized maize starch, sodium chloride, and stearic acid.

Lamotrigine orally disintegrating tablets are formulated using granulation technology in which the lamotrigine drug substance is granulated with stearic acid and eudragit EPO for taste masking. The formulation contains flavor and has a good mouth feel, no grittiness, no after taste, better palatability and gives a desired dissolution profile.
Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.
Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
BACKGROUND: Preimplantation genetic testing (PGT) is a reproductive technology that selects embryos without (familial) genetic variants. PGT has been applied in inherited cardiac disease and is included in the latest American Heart Association/American College of Cardiology guidelines. However, guidelines selecting eligible couples who will have the strongest risk reduction most from PGT are lacking. We developed an objective decision model to select eligibility for PGT and compared its results with those from a multidisciplinary team.
METHODS: All couples with an inherited cardiac disease referred to the national PGT center were included. A multidisciplinary team approved or rejected the indication based on clinical and genetic information. We developed a decision model based on published risk prediction models and literature, to evaluate the severity of the cardiac phenotype and the penetrance of the familial variant in referred patients. The outcomes of the model and the multidisciplinary team were compared in a blinded fashion.
RESULTS: Eighty-three couples were referred for PGT (1997-2022), comprising 19 different genes for 8 different inherited cardiac diseases (cardiomyopathies and arrhythmias). Using our model and proposed cutoff values, a definitive decision was reached for 76 (92%) couples, aligning with 95% of the multidisciplinary team decisions. In a prospective cohort of 11 couples, we showed the clinical applicability of the model to select couples most eligible for PGT.
CONCLUSIONS: The number of PGT requests for inherited cardiac diseases increases rapidly, without the availability of specific guidelines. We propose a 2-step decision model that helps select couples with the highest risk reduction for cardiac disease in their offspring after PGT.
The present invention provides an isolated DNA molecule that codes for a cell-surface binding protein in human monocytes and macrophages. In addition, an amino acid sequence derived from the nucleotide sequence is provided. The newly-identified cell-surface binding protein described herein is instrumental in the apoB-mediated cellular uptake of plasma chylomicrons and remnants and hypertriglyceridemic triglyceride-rich lipoproteins in an ApoE- and lipoprotein lipase- and heparin sulfate proteoglycan-independent pathway. The new human macrophage receptor has been cloned and uniquely, binds TGRLP via apolipoprotein B48, the marker of dietary TGRLP (apoB48R). This process rapidly converts macrophages and apoB48R-transfected Chinese hamster ovary cells in vitro into lipid-filled "foam cells," hallmarks of atherosclerotic lesions. The apoB48R cDNA (3744 bp) encodes a novel protein with no known homologs. Its ~3.8 kb mRNA is expressed primarily by reticuloendothelial cells. Immunohistochemical studies indicate that foam cells of human atherosclerotic lesions express the apoB48R.
The effect of oliceridine on cardiac physiology was studied in single and multiple-dose thorough QT studies. The multiple-dose study was conducted with a maximum daily cumulative dose of 27 mg. In both studies, there was mild QTc interval prolongation. In the multiple-dose study, the maximum mean ΔΔQTcI was 11.7 ms (two-sided 90% UCI 14.7 ms) at 9 hours. The effect on QT prolongation at total cumulative daily doses >27 mg has not been studied in a thorough QT study [see Clinical Pharmacology (12.2)]. Total cumulative daily doses exceeding 27 mg per day may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg [see Dosage and Administration (2.2)].
Clinical studies of perphenazine products did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic function, concomitant disease or other drug therapy.  
  
Geriatric patients are particularly sensitive to the side effects of antipsychotics, including perphenazine. These side effects include extrapyramidal symptoms (tardive dyskinesia, antipsychotic-induced parkinsonism, akathisia), anticholinergic effects, sedation and orthostatic hypotension (See WARNINGS). Elderly patients taking psychotropic drugs may be at increased risk for falling and consequent hip fractures. Elderly patients should be started on lower doses and observed closely.
PROBLEM TO BE SOLVED: To produce a new compound, having strong hypoglycemic actions and useful as a therapeutic agent for diabetes and complications thereof. SOLUTION: This compound is represented by formula I (R<1> is a substituted phenyl, naphthalene which can be substituted with a lower alkyl or a substitutable 5- or 6-heterocyclic ring; R<2> and R<3> are each H or a lower alkyl; A is a lower alkoxy or =O; B is H, a lower alkyl, a lower alkoxy, etc.; either one of dotted line parts is a single bond and the other is a double bond), e.g. 5-[(1,3-benzodioxol-5-yl)methyl]-2-methylthio-6-trifluoromethyl-4(3H)- pyrimidinone. The compound represented by formula I is produced by reacting a β-keto ester derivative represented by formula II (R<4> is a lower alkyl) with a compound or a thiourea represented by formula III (R<5> is H, a lower alkylthio or a lower alkyl) in a solvent (e.g. methanol) at ambient temperature to the refluxing temperature of the solvent.
Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Relates to recombinant ancrod enzyme, an industrial scale preparation method and application in treating acute cerebral infarction. Specifically, the recombinant ancrod enzyme has an amino acid sequence single chain shown in the specification, and is glycoprotein with the average molecular weight of 39-41 KDa, the molecular weight range of 33-52 KDa and the modified sugar content of more than 19%. Also relates to a preparation method, a cell culture method and a purification method of the recombinant ancrod enzyme and application of the recombinant ancrod enzyme in treating acute cerebral infarction. The recombinant ancrod enzyme of the invention has obviously better performance than natural ancrod enzyme. The method can obtain the recombinant ancrod enzyme with high expression quantity according to the industrial production specification, the yield can reach more than 200IU/ml of fermentation liquor per milliliter, and the specific activity can reach 1000 IU/mg. The recombinant ancrod enzyme has more complex and complete glycosylation level, obviously enhances the stability, and solves the problems of low expression level and difficult industrialization of the ancrod enzyme.